Bullish Momentum: (QNTM) In Spotlight Early This Morning On Approx. 115% Move This Week

*Sponsored Krypton Street Announces Quantum BioPharma (NASDAQ: QNTM) Is Back On Our Radar This MorningAfter Making An Approx. 566% Move Since Last Time. Today is Friday, March 28th, 2025 Here’s What We Can Tell You—So Far… Ultra Low Float With Fewer Than 1.6M Shares Publicly Available Approx. 566% Move Since Last Coverage Announcement Session-To-Session “One Day Moves” Of Approx. 145%, 213%, And 111% Trending Above All Major Moving Averages  Triggering 15 Bullish Signals—Just This Afternoon Alone Phase 1 Trial Completed, Product Expansion Underway Get Quantum BioPharma (NASDAQ: QNTM) On Your Screen While  It’s Still Early… March 28, 2025 Dear Reader, Please tell me you’re watching (QNTM) right now. Momentum, major news, and a float this tight don’t collide very often—but when they do, things can escalate fast. Quantum BioPharma (NASDAQ: QNTM) came out swinging this morning—hitting $11.49 in the early session, marking an approx. 115% move from Monday’s $5.32 range (3/24/2025)—right on the heels of fresh news that flipped the script on its balance sheet. With $12.1M in ca-sh, the removal of its “going concern” warning, and multiple catalysts already in motion, (QNTM) could quickly turn heads again. Oh—and it didn’t stop there.   This morning, (QNTM) was already lighting up 16 bullish signals on TradingView’s 5-minute chart, including the widely followed “Momentum Indicator” by 8:00 AM EST. We have all eyes on Quantum BioPharma (NASDAQ: QNTM) right now after it moved approximately 566% since the last time we initiated coverage. Get (QNTM) on your screen before the bell rings—the bell rings in about 15 minutes. This profile is in one of my favorite sectors—BioPharma.  In this sector, one major development can turn a little-known company into a headliner practically overnight. That’s why Quantum BioPharma (NASDAQ: QNTM) is topping our watchlist this morning. And now, with multiple catalysts in motion, it may not stay under the radar much longer. Initial Momentum Looks Strong—Eyes Are Now on What’s Next… There’s a certain kind of setup that grabs your attention—tight float, technical strength, and a chart that doesn’t sit still for long. Add in growing buzz, a strong narrative, and real movement under the surface... and suddenly, you’ve got something that’s hard to ignore. That’s exactly what’s unfolding here—and based on recent action, it may already be shifting into a higher gear. Since we last brought Quantum BioPharma (NASDAQ: QNTM) to your radar, it hasn’t just moved—it’s exploded. We’re talking about an approx. 566% move, rising from around $2.70 on 12/20/2024 to $18.00 by 2/6/2025. And here’s the part that turns heads: approx 506% of that move played out in just four sessions. Yet even with that kind of move, Quantum BioPharma (NASDAQ: QNTM) appears to be one of those companies that still flies under the radar—with a market cap just around $20M.  Historically, this is the range where lesser-known names have made some of their biggest moves—especially when the right catalyst hits. And technically?  It’s still flashing strength. Quantum BioPharma (NASDAQ: QNTM) is currently trending above every major moving average tracked by Barchart, including: 5-Day: 6.39 20-Day: 5.46 50-Day: 5.97 100-Day: 5.17 200-Day: 6.05 Year-to-Date: 5.66 In fact, this afternoon, Quantum BioPharma (NASDAQ: QNTM) lit up 15 Bullish Signals, including the “Momentum Indicator” on TradingView’s technical analysis dashboard—adding confidence as we head into today's session. But there’s another element that can’t be ignored… A Float This Thin Can Move Fast… One of the most important dynamics to understand here is supply—or more accurately, the lack of it. As of now, there’s less than 1.6M shares of Quantum BioPharma (NASDAQ: QNTM) listed as publicly available in its float.  That’s considered ultra low float territory, where even modest interest can create sharp moves simply due to scarcity. And this isn’t theoretical. It’s already played out in recent sessions. A Float This Thin Doesn’t Stay Quiet for Long One of the most overlooked situations in the market is how quickly things can shift when supply runs tight.  It’s not always about buzz or momentum—sometimes, it's the structure behind the ticker that sets everything in motion. When a name has an ultra low float, even a slight uptick in demand can tip the scale.  Not because of hype—but because there just aren’t many shares available to begin with. That’s what makes this such a special situation.  Quantum BioPharma (NASDAQ: QNTM) has fewer than 1.6M shares publicly available in its float, placing it in a zone where scarcity alone has the potential to drive fast, aggressive moves if attention begins to shift. And we’re not talking theory—it’s already played out.  Multiple sessions in recent months have shown how quickly this name can move when interest begins to build. Take A Look at These Recent Moves… 111%, 145%, 213% (Approx.)  Moves In Just One Day…  We’ve seen multiple breakout-style moves—some in under 24 hours, others across just a few trading days. And just this morning (3/27/2025), we saw another example play out in real time—an approx. 29% move from $7.02 in the pre-market to $9.08 before lunch. Approx. 145% move in under 24 hours From $2.97 on Mon 02/03/2025 to $7.28 on Tue 02/04/2025 Approx. 213% move in under 24 hours From $5.75 on Wed 02/05/2025 to $18.00 on Thu 02/06/2025 Approx. 86% move from session to session From $4.60 on Fri 03/14/2025 to $8.60 on Mon 03/17/2025 Approx. 111% move in under 24 hours From $4.76 on Tue 02/04/2025 to $10.05 on Wed 02/05/2025 Approx. 506% move in under 4 days From $2.97 on Mon 02/03/2025 to $18.00 on Thu 02/06/2025 With momentum building and a float this tight, it’s no surprise Quantum BioPharma (NASDAQ: QNTM) is topping our watchlist this morning. So let’s break down exactly what this company is building—and why it’s starting to turn heads across both the consumer health and biopharma worlds. Focused on Urgency, Not Hype… Addressing Real-World Challenges with a Lean, Focused Model Quantum BioPharma (NASDAQ: QNTM) is taking aim at two widespread issues that carry both human and system-wide impact: alcohol misuse and degenerative neurological conditions like multiple sclerosis (MS). Rather than spreading across broad categories, the company is going deep—pairing advanced R&D with a capital-efficient model that allows for speed, scalability, and strategic partnerships. unbuzzd™: The Consumer Launch Gaining Traction Through a 25.71% equity stake in Celly Nutrition, (QNTM) is tied to unbuzzd™—a fast-acting alcohol detox supplement scientifically formulated to accelerate alcohol metabolism and restore alertness within 15–30 minutes. Clinical trials showed significant reductions in perceived impairment and BrAC, and distribution is already scaling across e-commerce with retail expansion underway. Quantum BioPharma (NASDAQ: QNTM) benefits through a royalty structure—7% on gross sales until $250M is reached, followed by 3% in perpetuity—while also retaining 100% of pharmaceutical and medical rights tied to the formulation. rekvry™: Designed for Critical Care rekvry™ is currently in development for emergency room and hospital use—targeting a high-need setting that still lacks modern recovery options. QNTM owns full medical and pharmaceutical rights, adding strategic depth to its alcohol health pipeline—consumer and clinical. Advancing a New Approach to MS… Quantum BioPharma (NASDAQ: QNTM) is advancing LUCID-21-302, a novel therapeutic targeting demyelination, the core issue behind multiple sclerosis (MS)—a condition that affects nearly 1M people in the U.S. and 2.8M globally. Backed by over 14 years of preclinical R&D, LUCID-21-302 has shown encouraging results in animal studies, including improved functional recovery and myelin preservation. The Phase 1 trial has been completed with no serious adverse effects reported, and a Phase 2 trial is expected in early 2026. Unlike most MS therapies, this candidate takes a non-immunosuppressive approach—setting it apart in a space that continues to seek better long-term answers. Quantum BioPharma (NASDAQ: QNTM) holds exclusive global rights to this compound, with potential applications extending beyond MS into other demyelinating conditions. Meet the Builders Behind the Breakthroughs… This team has done it before—and now, they're the minds driving the momentum behind the scenes. Quantum BioPharma (NASDAQ: QNTM) is led by a mix of scientific, commercial, and operational veterans with a record of high-impact execution: -Kevin Harrington – Original Shark Tank member and brand-builder with $6B+ in sales across global markets -Dr. Lakshmi Kotra, PhD – A renowned medicinal chemist with a portfolio of successful dru-g development programs -Dr. Eric Hoskins – Former Ontario Minister of Health with decades of experience in public healthcare systems -Gerry David – The executive behind Celsius Holdings’ 35x rise in value during his leadership -Zeeshan Saeed – Capital markets strategist and Quantum’s founding CEO Together, they bring experience across every part of the development-to-launch cycle—from lab to shelf, from regulatory filings to go-to-market partnerships. Latest Developments… March 27, 2025 – Leading Crusader Against Market Manipulation Joins the Board Quantum BioPharma (NASDAQ: QNTM) announced the appointment of Terry Lynch to its Board of Directors. Lynch is widely recognized for founding Save Canadian Mining, an organization actively challenging naked short selling and micro-cap manipulation. He brings extensive experience across biotech, capital markets, and company-building. Lynch replaces Dr. Sanjiv Chopra, who will continue as an advisor to the company. Learn More→ March 26, 2025 – Celly Nutrition Expands unbuzzd™ Product Lineup for Retail Quantum BioPharma (NASDAQ: QNTM)’s licensee, Celly Nutrition, announced the expansion of its alcohol detox product, unbuzzd™, with new retail-ready formats designed for broader consumer access. The rollout includes updated packaging and display configurations to support placement at point-of-sale counters nationwide.  Full announcement → March 20, 2025 – Further Diversification with $1.5M in Digital Assets Quantum BioPharma (NASDAQ: QNTM) disclosed an additional $1.5M purchase of B-T-C and other cry-pto-curren-cies, marking another step in its ongoing treasury diversification strategy. This builds on previous cry-pto acquisitions aimed at strengthening long-term fiscal flexibility. Full story → February 26, 2025 – Phase 1 Trial Completed for MS Dr-ug LUCID-21-302 Quantum BioPharma (NASDAQ: QNTM) announced the successful completion of its Phase 1 Multiple Ascending Dose (MAD) trial for LUCID-21-302, its lead asset for demyelinating diseases. The study reported no serious dr-ug-related adverse events, paving the way for a Phase 2 trial expected to begin in 2026. Read more → Quantum BioPharma (NASDAQ: QNTM) isn’t chasing headlines—it’s building momentum where it matters most. While the broader market jumps from one theme to the next, QNTM continues to focus on long-term, science-driven initiatives with a model built for speed, flexibility, and focus. Whether it’s accelerating alcohol metabolism, pushing forward in neuro recovery, or moving faster than larger names weighed down by overhead—this is a company that stands out. And right now, it’s topping our watchlist for a reason. 5 Reasons Why Quantum BioPharma (NASDAQ: QNTM) is Topping Our Watchlist This Morning—Friday 3/28/2025… 1. Ultra Low Float: With fewer than 1.6M shares publicly available, (QNTM) sits in a range where supply is limited—and past moves show how quickly things can shift when attention builds. 2. Recent Momentum Has Been Hard to Ignore: Since December 2024, (QNTM) moved from $2.70 to $18.00—an approx. 566% move, with one of those surges (approx. 506%) playing out in just four sessions. 3. Breakout Sessions: In recent months, (QNTM) has made session-to-session moves of approx. 145%, 213%, and 111%—showcasing how reactive it can be under the right conditions. 4. Strong Technical Confirmation: (QNTM) is trending above every major moving average tracked by Barchart, including its 5-day, 20-day, 50-day, and 200-day levels. It also triggered 15 bullish signals on TradingView this afternoon. 5. Multiple Catalysts Already in Motion: Recent developments include the completion of a Phase 1 trial for LUCID-21-302, a retail product expansion for unbuzzd™, and ongoing treasury diversification moves—all within the past month. Get Quantum BioPharma (NASDAQ: QNTM) On Your Screen  While It’s Still Early… Quantum BioPharma (NASDAQ: QNTM) isn’t just showing signs of strength—it’s actively executing across multiple fronts. From consumer health to neuro recovery, the company is advancing real-world solutions, triggering bullish signals across platforms, and doing it all with a lean model that allows it to move fast. Combine that with an ultra low float and a recent pattern of fast-moving sessions—and this setup deserves a serious look. Momentum has already made an appearance.  But with several catalysts still in motion, this could just be the start. We have all eyes on (QNTM) right now after it moved approximately 566% since the last time we initiated coverage. If you missed my earlier email, this profile is in one of my favorite sectors—BioPharma. In this sector, one major development can turn a little-known company into a headliner practically overnight. That’s why (QNTM) is topping our watchlist this morning. (QNTM) came out swinging this morning—hitting $11.49 in the early session, marking an approximate 115% move this week—while triggering 16 bullish signals by 8AM EST this morning. Do you have (QNTM) on your screen yet? Keep an eye out for my next update—it could be coming at any moment. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: kryptonstreet.com/disclaimer/ *Quantum BioPharma Ltd. (QNTM:US) (QNTM:CA) previously changed their company name and symbols from FSD Pharma Inc. (HUGE:US) (QNTM:CA). Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 03/26/2025 and ending on 03/31/2025 to publicly disseminate information about (QNTM:US) (QNTM:CA) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid forty two thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Quantum BioPharma Ltd., the issuer of (QNTM:US) (QNTM:CA). Neither Media 1717 LLC, TD Media LLC and their member own shares of (QNTM:US) (QNTM:CA). Please see important disclosure information here: https://kryptonstreet.com/disclosure/qntm/#details

Media 1717 LLC | 6586 W Atlantic Ave Unit #2086 | Delray Beach, FL 33446 US Unsubscribe | Update Profile | Constant Contact Data Notice